Neurofibromatoses - Pipeline Review, H2, Pharmaceutical 2016
Albany, New York, Jan 19,2017
"Neurofibromatoses
- Pipeline Review, H2 2016"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Neurofibromatoses Pipeline Review, H2 2016, provides
an overview of the Neurofibromatoses (Genetic Disorders) pipeline
landscape.
Neurofibromatosis
(commonly abbreviated NF; neurofibromatosis type 1 is also known as
von Recklinghausen disease) is a genetically-inherited disorder in
which the nerve tissue grows tumors (neurofibromas) that may be
benign or may cause serious damage by compressing nerves and other
tissues. The disorder affects all neural crest cells (Schwann cells,
melanocytes and endoneurial fibroblasts). Cellular elements from
these cell types proliferate excessively throughout the body, forming
tumors; melanocytes also function abnormally in this disease,
resulting in disordered skin pigmentation and caf au lait spots. The
tumors may cause bumps under the skin, colored spots, skeletal
problems, pressure on spinal nerve roots, and other neurological
problems.
*
Report Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Neurofibromatoses Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for
Neurofibromatoses (Genetic Disorders), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of
key players involved in therapeutic development for Neurofibromatoses
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II, Phase
0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively.
Similarly, the Universities portfolio in Phase II, Preclinical and
Discovery stages comprises 1, 1 and 1 molecules, respectively.
Neurofibromatoses
(Genetic Disorders) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time
basis.
*
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Neurofibromatoses (Genetic Disorders).
-
The pipeline guide reviews pipeline therapeutics for
Neurofibromatoses (Genetic Disorders) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in
Neurofibromatoses (Genetic Disorders) therapeutics and enlists all
their major and minor projects.
-
The pipeline guide evaluates Neurofibromatoses (Genetic Disorders)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Neurofibromatoses (Genetic Disorders)
*
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Neurofibromatoses (Genetic Disorders).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Neurofibromatoses (Genetic Disorders) pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Comments
Post a Comment